Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEL-212 in Refractory Gout (DISSOLVE I)
NCT04513366Phase 3Completed
- Sponsor
- Sobi
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SEL-212 in gout (3 arms), sponsored by Sobi. Primary endpoint: Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 mg/dL for At Least 80% of The Time During Treatment Period 6 at Month 6. Started Aug 2020; status: completed.
02
Drugs
SEL-212
03
Conditions
gout
Beyond the preview
Go deeper on NCT04513366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513366.